Page Banner
Mayo Clinic Laboratories > Neurology > Alzheimer’s disease

Alzheimer’s disease

Accurate answers to guide care

The swift pace of research and discovery around Alzheimer’s disease has yielded new treatments that, more than ever before, give patients a reason to hope. Early, accurate diagnosis is important to access FDA-approved medications and improve patient care.

Our complete menu of innovative Alzheimer's disease evaluations includes both blood and cerebrospinal fluid (CSF) biomarkers to achieve a high concordance with amyloid positron emission tomography (PET) scans. Using the most up-to-date methodology — automated immunoassay with innovative instrumentation — these tests are clinically validated in our lab and optimized to reduce pre-clinical variability. Offering precision measurements and a fast time to results, our Alzheimer’s assays deliver accurate answers that can improve access to Alzheimer’s disease treatments.

Alzheimer’s disease Test menu

Plasma biomarker testing

Alzheimer’s disease remains a challenge to diagnose, however, heightened understanding of the role of blood biomarkers has enabled the development of noninvasive blood tests that provide a diagnostic tool to aid in the evaluation of patients presenting with mild cognitive impairment or early dementia. Our plasma-based assay evaluates for phosphorylated Tau 217 (p-Tau217), which provides the highest diagnostic accuracy and specificity for the detection of amyloid pathology.  

Key testing

Advantages

  • Noninvasive blood test with a rapid time to result (1–5 days).
  • Assesses pathological accumulation of beta amyloid in the brain by measuring the amount of phosphorylated Tau 217 (p-Tau217) in plasma.
  • Provides high diagnostic accuracy for the detection of brain amyloid pathology as assessed by amyloid PET imaging.
  • Test interpretation cutpoints have been optimized to obtain an overall 92% sensitivity and 96% specificity for the detection of abnormal amyloid pathology based on amyloid-PET positivity.
  • Uses a two-cutpoint model of result interpretation, which maximizes the overall testing accuracy.
    • A positive result is consistent with the presence of amyloid pathology and supports an Alzheimer’s disease diagnosis; a negative result indicates a reduced likelihood that an individual has neuropathological changes associated with Alzheimer’s disease; and an intermediate result cannot accurately differentiate between the presence or absence of neuropathological changes associated with Alzheimer’s disease.
    • In the case of an intermediate result, additional testing, such as amyloid PET or CSF pTau181/Aβ42 or CSF Aβ42/Aβ40 ratio, is recommended.
  • Promotes increased access to dementia evaluation and potential treatment.
  • Recommended for patients age 55 and older who present with symptoms of mild cognitive impairment or early dementia.
  • This test is NOT intended for asymptomatic patients.
  • Note: Patients with advanced chronic kidney disease may have elevated levels of p-Tau217. In these instances, careful evaluation of a positive result is required.

Mayo Clinic Laboratories also offers the following testing from C2N Diagnostics

Advantages

  • FDA-cleared, noninvasive blood test with turnaround time of 13 days.
  • Measures core biomarkers of Alzheimer’s disease to assess the presence of amyloid pathology in the brain.
  • Uses highly accurate liquid chromatography-tandem mass spectrometry (LC-MS/MS), a leading analytical platform for protein quantitation,2,3 to measure Aβ42, Aβ40, p-tau217, and non-phosphorylated tau217 (np-tau217).4
  • Combines two ratios — Aβ42/40 and %p-tau217(p-tau217/non-p-tau217) — into a clinically and analytically validated algorithm to generate the Amyloid Probability Score 2 (APS2), a numeric value ranging from 0 to 100.
    • Use of biomarker ratios can improve diagnostic performance and help account for variability associated with advancing age and comorbidities such as chronic kidney disease, anemia, and obesity.5-7
  • Uses two clinical cutoffs to provide three result categories:
    • Positive (APS2 > 66.5): Consistent with the presence of brain amyloid pathology and increases the likelihood that a patient’s clinical presentation is due to Alzheimer’s disease.
    • Likely positive (APS2 > 27.5 and < 66.5): Likely consistent with the presence of brain amyloid pathology and increases the likelihood that a patient’s clinical presentation is due to Alzheimer’s disease. Additional evaluation and/or further testing may be appropriate.
    • Negative (APS2 < 27.5): Not consistent with the presence of brain amyloid pathology and decreases the likelihood that a patient’s clinical presentation is due to Alzheimer’s disease.

*This test is:

  • Indicated for adults age 40 and older who present with signs or symptoms of cognitive impairment and are undergoing evaluation for Alzheimer’s disease or other forms of cognitive decline.
  • Intended for use in conjunction with clinical assessment by healthcare professionals experienced in evaluating cognitive impairment. The APS2 result alone does not establish a diagnosis of clinical Alzheimer’s disease. The test is not intended as a screening or stand-alone diagnostic test.

Highlights


Cerebrospinal fluid biomarker testing

The results from our CSF evaluations are based on ratios of p-Tau and AB42 (Mayo ID: ADEVL) and AB42 and AB40 (Mayo ID: AMYR), which allow for greater than 90% diagnostic accuracy compared to standard assessments. We also use low-binding tubes, resulting in fewer falsely abnormal results for patients.

Key testing

Advantages

  • Uses the most up-to-date methodology (automated immunoassay).
  • Evaluates multiple biomarkers and ratios.
  • Aligns with consensus research diagnostic criteria for Alzheimer’s disease, mild cognitive impairment (MCI), and pre-clinical Alzheimer’s disease as proposed by the National Institute on Aging and Alzheimer’s Associate Research Framework.8
  • AMYR is an FDA-approved evaluation.
  • Positive result enables access to FDA-approved medications.

When to consider testing

  • For the differential diagnosis of Alzheimer’s disease versus other causes of cognitive impairment.
  • When patients present with atypical dementia symptoms.
  • To assess Alzheimer’s disease pathology in a mixed diagnosis.
  • To allow for eligibility into clinical trials.

More information

Clear results that guide treatment decisions

A diagnosis of Alzheimer’s disease can change patients' lives. Receiving a fast, definitive answer from a healthcare institution they trust can provide hope and a plan for their future. Whether it is the right treatment for symptom management, confirmation of diagnosis, or eligibility for clinical trials, we are here to provide the highest quality of care. 

Fast, cost-effective answers when you need them the most

A differential diagnosis can change treatment and improve patient care. With our testing, a patient receives the answers they need in as little as one day. They don’t have to wait weeks or months to be placed on the right treatment and start planning for their future.

A complementary solution to assist with diagnosis

Standard assessment of suspected Alzheimer's disease patients through clinical and cognitive assessment is 70%–80% accurate. By adding our Alzheimer's disease evaluations, physicians can increase diagnostic accuracy by 12%–22% to ensure they are providing the correct diagnosis and treatment for patients.

Confirm neuronal damage

For patients suspected of having Alzheimer’s disease, testing for neurofilament light chain (NfL), a generic marker of neurodegeneration, can confirm a neurodegenerative disease process. Mayo Clinic Laboratories has developed an innovative assay to test for elevated levels of NfL in the blood. Positive test results not only confirm neuronal damage but can offer insights on disease progression and prognosis to guide therapeutic decision-making.

Highlights


Dementia with Lewy bodies and Alzheimer’s disease with mixed pathology

The SAAmplify™–αSYN is a unique seed amplification assay that identifies misfolded α-synuclein in cerebrospinal fluid. Designed for individuals with clinically uncertain neurodegeneration, results can help diagnose dementia with Lewy bodies (DLB) and Alzheimer's disease with Lewy body pathology (AD-LB) even before the appearance of definitive symptoms.

Key testing


Glial fibrillary acidic protein

Glial fibrillary acidic protein (GFAP) is an astrocyte-specific protein that is released into biofluids during astrocyte activation resulting from trauma, neurodegenerative conditions, neuroinflammation, and other factors.

There is a growing body of evidence that supports the use of GFAP as a biomarker for early detection of Alzheimer’s disease. Multiple research studies have found a correlation between elevated GFAP concentration in the blood and Aβ pathology in the brain, with rising GFAP levels observed in the preclinical stage of Alzheimer’s disease.11,12,13 Studies have also found that in patients with mild cognitive impairment, elevations of GFAP concentrations have been reported to be reflective of increased risk of progression to Alzheimer’s disease dementia. Further, individuals who have elevated blood concentrations of both GFAP and other Aβ or Tau biomarkers are at risk for faster disease progression than patients without elevated GFAP concentrations.14

Used in combination with other first-line plasma tests for Alzheimer’s disease, GFAP test results may aid with differential diagnosis to establish the correct cause of neurodegeneration as well as to better understand disease progression.

Key testing


Neurofilament light chain

Neurofilament light chain (NfL) is a nonspecific protein biomarker that corresponds to neuro-axonal damage, with elevated NfL concentrations in blood linked to several neurodegenerative disease states, including Alzheimer’s disease. In a meta-analysis of patients with Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS), plasma NfL levels were elevated.

Propelled by Mayo Clinic-led research, our first-in-class assay tests for an elevated NfL level in the blood. Positive test results not only confirm neuronal damage but can offer insights on disease severity, progression, and prognosis to guide therapeutic decision-making.

Key testing


References
  1. Alzheimer’s Association. 2023 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2023;19(4):1598-1695. doi:10.1002/alz.13016
  2. Pan S, Aebersold R, Chen R, et al. Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res. 2009;8(2):787-797. doi:10.1021/pr800538n
  3. Bravo-Veyrat S, Hopfgartner G. Mass spectrometry based high-throughput bioanalysis of low molecular weight compounds: are we ready to support personalized medicine? Anal Bioanal Chem. 2022;414(1):181-192. doi:10.1007/s00216-021-03583-2
  4. Meyer MR, Kirmess KM, Eastwood S, et al. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. Alzheimers Dement. 2024;20(5):3179-3192. doi:10.1002/alz.13764
  5. Bornhorst JA, Lundgreen CS, Weigand SD, et al. Quantitative assessment of the effect of chronic kidney disease on plasma p-Tau217 concentrations. Neurology. 2025;104(3):e210287. doi:10.1212/WNL.0000000000210287
  6. Yun J, Lee J, Shin D, et al. Plasma phosphorylated tau 217 cutoffs for amyloid pathology and kidney function, body mass index, and anemia. JAMA Neurol. 2026;83(3):269-279. doi:10.1001/jamaneurol.2025.5530
  7. Pichet Binette A, Janelidze S, Cullen N, et al. Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023 Apr;19(4):1403-1414. doi: 10.1002/alz.12787. Epub 2022 Sep 24.
  8. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018 Apr;14(4):535-562. doi:10.1016/j.jalz.2018.02.018. PMID: 29653606; PMCID: PMC5958625.
  9. Ma Y, Farris C, Weber S, et al. Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study. Lancet Neurol. 2024 Dec;23(12):1225-1237.
  10. Rossi M, Candelise N, Baiardi S, et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 2020 Jul;140(1):49-62. https://doi.org/10.1007/s00401-020-02160-8. Epub 2020 Apr 27. Erratum in: Acta Neuropathol. 2020 Aug;140(2):245. https://doi.org/10.1007/s00401-020-02170-6 PMID: 32342188; PMCID: PMC7299922.
  11. Kim KY, Shin KY, Chang KA. GFAP as a potential biomarker for Alzheimer's disease: a systematic review and meta-analysis. Cells. 2023 May 4;12(9):1309. doi:10.3390/cells12091309. PMID: 37174709; PMCID: PMC10177296.
  12. Bandara, E.M.S., Asih, P.R., Pedrini, S. et al. The role of glial fibrillary acidic protein in the neuropathology of Alzheimer’s disease and its potential as a blood biomarker for early diagnosis and progression. Mol Neurobiol 62, 15576–15608 (2025). https://doi.org/10.1007/s12035-025-05219-3
  13. Oeckl, Patrick, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment. Journal of Alzheimer’s Disease 67.2 (2019): 481-488. 
  14. Cicognola, C., Janelidze, S., Hertze, J. et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alz Res Therapy 13, 68 (2021). https://doi.org/10.1186/s13195-021-00804-9
  15. Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s Dement. 2024;20(8):5143-5169. doi:10.1002/alz.13859
(BETA) Choose a language to view this content in:
About the translation.